Skip to content
Search

Latest Stories

MHRA approved nicotine inhaler system by Ayrton Saunders for general sale

MHRA approved nicotine inhaler system by Ayrton Saunders for general sale
Available in pharmacies, the Ayrton Saunders' nicotine inhaler system is "first NRT that delivers nicotine directly for absorption in the lung"

Speciality pharmaceutical company Ayrton Saunders Limited said it has received approval from the UK drugs regulator Medicines and Healthcare products Regulatory Agency (MHRA) for its nicotine inhaler system.

The Liverpool based company, part of OBG Pharma, said the product is the world’s first and only clinically approved, patented nicotine inhaler system able to deliver nicotine directly via the lungs to help smokers replace, cut down and ultimately quit smoking.


The company is working to extend this landmark approval to additional markets in the EU and beyond and will explore discussions regarding regulatory and commercial pathways in the US and Japan.

They are also actively seeking partners for commercial launch of this novel nicotine-replacement therapy (NRT) in the UK and other key markets.

As a General Sales List (GSL) medicine, it can be offered for sale with or without prescription.

“The harms caused by tobacco smoking place a huge health and economic burden on society, and while currently available smoking cessation products can help, they are not appropriate for most smokers trying to quit,” Gerry O’Brien, director of Ayrtons, said.

“We are delighted to create and offer for license or sale a product that we believe will play a crucial role in helping to combat tobacco dependence and improve public health as we work towards a healthier, more smoke-free world.”

First NRT for Direct Lung Nicotine Absorption

O’Brien has spearheaded the development and significant re-design of the product over the past three years following initial development work by Kind Consumer Ltd.

The company said this has resulted in improved device function and user experience, while at the same time delivering a reduced price point for consumers.

“The team has worked tirelessly to reach this important milestone of MHRA approval making this product the first NRT that delivers nicotine directly for absorption in the lung,” stated O’Brien.

“Ten million adults in the UK smoke or vape and half of these people try to quit each year, but fewer than 3 per cent succeed.

"Smoking is the leading cause of premature, preventable death in the UK and globally, so there is a crucial need for widespread access to services and products that have been shown to help smokers reduce or stop smoking safely and cost-effectively.”

Using globally patented technology similar to an asthma inhaler, this innovative next-generation system enables rapid delivery via the lungs of a low dose of nicotine that quickly reaches the brain to provide fast and safe relief of craving symptoms.

It has a fresh, clean taste and no noticeable smell or visible exhalate when fully inhaled.

The system consists of a reusable, hand-held breath-activated inhaler device and a stable (flavoured) nicotine solution.

Powered by a pressurised propellant, no batteries are required and there is no heat and no change to the chemical structure of the formulation when generating the aerosol.

The product is refillable using nicotine canisters, which enables an attractive price point for the consumer.

The product has undergone extensive user testing and clinical trials, which demonstrated a bigger reduction in craving relative to the market leading inhalator device, the company claimed.

It is now uniquely positioned in the UK market to be offered for sale (with or without prescription) and advertised on major e-commerce platforms, via pharmacies and direct-to-consumer channels that are regulatorily restricted for vapes or e-cigarettes.

More For You

Celebrating Waheedat Owodeyi’s inspiring journey

Waheedat Owodeyi, owner and superintendent pharmacist, Pharmacyexprezz

Empowering female pharmacists

Despite the high number of registered female pharmacy professionals, women remain underrepresented in leadership roles across the sector.

“That’s a shame because women bring a different and valuable perspective to leadership,” said Waheedat Owodeyi, owner and superintendent pharmacist, Pharmacyexprezz in Great Yarmouth.

Keep ReadingShow less
Pharmacy First struggles: "I've barely completed 10 cases in a year," says pharmacist

Waheedat Owodeyi, owner and superintendent pharmacist at Pharmacyexprezz

Pharmacy First needs an online booking system, just like COVID and Flu services

A growing number of community pharmacies are closing permanently, mainly due to chronic underfunding and inadequate reimbursement.

Waheedat Owodeyi, owner and superintendent pharmacist at Pharmacyexprezz, said that financial pressures are not exclusive to traditional brick-and-mortar pharmacies—online pharmacies face the same struggles.

Keep ReadingShow less
The success story of Easter Pharmacy – the winner of Pharmacy Clinical Excellence Award 2024

Left to Right: Shailesh Solanki, Stephen Kinnock MP, Babatunde Sokoyo, Harry McQuillan, Chairman of Numark, Kalpesh Solanki and Rory BremnerEaster Pharmacy’s commandments for success

Easter Pharmacy’s commandments for success

Fostering a strong relationship between pharmacists and GPs can help resolve many issues in primary care, particularly regarding access to appointments and urgent care.

With this belief, Babatunde Sokoya, pharmacist superintendent at Easter Pharmacy, in Buckhurst Hill, Essex, aims to further strengthen collaboration with local practices and position his pharmacy as a leading example of integrated pharmacy service nationwide.

Keep ReadingShow less
Samson Akere with the Totty Pharmacy team

Samson Akere with the Totty Pharmacy team

“Team work makes dream work”

Winning Team of the Year at the Pharmacy Business Awards, just one year after opening, is a reflection of the exceptional leadership Totty Pharmacy owner Samson Akere displayed to ensure his first foray into ownership was a success.

Akere took over the pharmacy in Charlton in October 2023 and straight away he set out on the path to create a diverse, multi-skilled team.

Keep ReadingShow less
Humanin Peptide: A Mitochondrial-Derived Factor with Potential Implications for Cellular Research

Humanin Peptide: A Mitochondrial-Derived Factor with Potential Implications for Cellular Research

Humanin is a mitochondrial-derived peptide (MDP) that has garnered interest due to its potential roles in cellular homeostasis, stress resistance, and metabolic regulation. Initially discovered in relation to neuroprotection, this small peptide has since been hypothesized to interact with multiple cellular pathways, suggesting its involvement in broader physiological processes. Given its origin from mitochondrial DNA (mtDNA), Humanin is believed to be a key player in mitochondrial communication with the nucleus and other cellular compartments, potentially impacting various research fields, including cellular aging, metabolic regulation, and cellular stress response.

Molecular Characteristics and Mechanisms

Keep ReadingShow less